Primary breast lymphoma is a rare form of non-Hodgkin lymphoma with some distinct clinical features. The most common histopathological type is diffuse large B-cell lymphoma (DLBCL), but other less frequent subtypes are also encountered. In this review, we describe the characteristics of primary breast DLBCL, with emphasis on pathogenesis, staging, risk stratification and prognosis. In addition, key issues regarding therapy and various available therapeutic modalities are addressed, as well as the role of rituximab in therapy and whether central nervous system prophylaxis is still routinely required. There are very few prospective clinical studies addressing therapy, and available data rely mostly on retrospective case series involving small numbers of patients. Our conclusions and proposed recommendations are therefore not offered as formal guidelines. This review attempts to represent an unbiased analysis of the published data and is intended as a useful aid for clinicians treating this uncommon type of extra nodal lymphoma.
but also raises the intriguing possibility of selective 'homing' of lymphoma cells to breast tissue, which may be mediated by cellular receptors and tissue chemo-attractants such as CXCL12 and CXCL13 as reported in other extranodal lymphomas [20] .
DLBCL subclasses
By using gene expression profiling and immunohistochemistry, DLBCL is currently classified into germinal center B cell (GCB) and activated B cell (ABC/non-GCB) subtypes, with the latter having a poorer outcome [21] [22] [23] .
Only a few studies have examined this subclassification in PBL, but results are interesting. A small series found that all 15 cases of PB-DLBCL described were of the non-GCB type [24] , whereas Aviles et al. [25] reported on 104 patients, of whom 80 cases (77%) were the non-GCB type; however, they had similar outcomes as their GCB counterparts. Similarly, Talwalkar et al. [4] found 65% of cases to be non-GCB with no apparent prognostic implications. Niitsu et al. [26] recently reported a non-GCB pattern in 57% of PB-DLBCL, showing a correlation with poor progression-free survival (PFS) but not overall survival (OS).
Furthermore, most recently, Yhim et al. [27] compared PBL and nodal DLBCL and also reported significantly higher rates of non-GCB in PBL (95% versus 62%, P < 0.001), with similar 3-year OS and PFS rates as the GCB cohort. Thus, in contrast to the general data on nodal DLBCL, there is striking predominance of the non-GCB type in PB-DLBCL, but its prognostic significance remains unclear.
relation to sex hormones
The overwhelming majority of patients with PBL are females; however, there are a few rare reports in males [3, 17, [28] [29] [30] [31] [32] . These obvious gender differences suggest that sex hormones may be important in pathogenesis. Additional support for this theory is the relatively high rate (5%-20%) of bilateral disease at diagnosis [3, 11, 33] . The influence of sex hormones on lymphocytes has been extensively studied, but detailed findings are beyond the scope of this review. Estrogen receptors (ERs) are selectively expressed on B lymphocytes, with differential expression of ERα and ERβ. ERβ expression has also been described in Hodgkin and Burkitt lymphoma cell lines as well as in lymphocytes within breast cancer tissue [34] . The activation of the ERβ pathway has an apoptotic and anti-proliferative effect on lymphocytes, but its precise role in lymphomagenesis remains uncertain [35] .
Suggestions for a possible link between lymphoma, estrogen and prolactin have also come from in vitro and epidemiological studies, but these remain inconclusive [34] [35] [36] [37] [38] [39] . There are only two reports referring to sex hormone expression in human PBL tissue. Ariad et al. [40] examined 11 PBL specimens and none of which stained positively for ER, whereas Hugh et al. [41] noted positive ER staining in two PBL tissue samples. Thus, there may be a link between sex hormones and development of NHL in general and PBL in particular, however, convincing data supporting this hypothesis are still inadequate.
low prevalence of systemic (B) symptoms
Baseline data from large clinical trials of DLBCL show that 25%-37% of patients have systemic symptoms [42] [43] [44] . However, in 26 original publications on PBL, the range was usually between 0% and 22% [1-7, 10, 14, 16, 17, 26, 28, 45-57] . A total of 906 patients were included in these studies and only 45 (5%) had B symptoms on presentation. This apparent lack of systemic symptoms probably relates to the fact that the vast majority of patients present early with only a palpable breast mass. Moreover, using the Wiseman-Liao criteria, patients with systemic involvement are excluded by definition thereby pre-selecting patients with localized disease and fewer chances of developing B symptoms. Indeed, considering the lymphoma international prognostic index (IPI), it is evident that the vast majority of PBL are in the low or low intermediate risk groups (Table 1) .
staging and prognostication
In practice, the Wiseman-Liao definition confines the clinical stage of PBL to Ann Arbor I E or II E, and patients are by definition 'early stage' [12] . The distinction between stages I E and II E (involvement of regional lymph nodes) is important because of significant differences in 5-year OS, for stage I E (78%-83%) compared with stage II E (20%-57%) [15, 16, 45, 53] . In this regard, the use of the positron emission tomography (PET) scan may discriminate the stages more accurately due to its high sensitivity in DLBCL. Data on PB-DLBCL are sparse, yet from the few cases described, it seems that PET yields similar advantages as in nodal DLBCL [58, 59] . The issue of performing interim PET for determining outcome or as a guide to stratify treatment is not as yet fully resolved for nodal DLBCL and was never reported in PBL and therefore will not be dealt with in this review.
Bilateral PBL, although rare, is still controversial with regard to stage and prognosis. The largest series of PB-DLBCL reported until now, classified cases with bilateral breast involvement as stage IV [3] , whereas others have defined them as stage I E [46] or II [45, 48, 53, 60, 61] . For the sake of uniformity, and in view of a possible worse prognosis of bilateral PBL [2, 4, 41, 46, 62] , these rare cases may well be classified as stage IV disease.
Stratification of PBL into risk groups is usually based upon the IPI [63] . Several reports of relatively small series have suggested alternative models for PBL prognostication, identifying increased microvessel density [45] or increased levels of soluble interleukin 2 receptor (>1000 U/ml) [26] as predictors of worse outcome. The report by the Consortium for improving the survival of lymphoma (CISL) summarized 68 cases of PB-DLBCL using the definition of one extranodal disease (OED) category when one breast was involved and multiple extranodal disease (MED) when additional extra nodal sites were present. In both categories, the presence of nodal disease was not considered relevant. The OED group had better 5-year PFS than the MED (64.9% versus 27.5%, respectively) and better 5-year OS (74.3% versus 24.5%, respectively) [2] .
The importance of tumor dimension has been noted by several investigators, with a size of 4-5 cm possibly predicting worse outcome [13, 16, 26, 46] . This cutoff probably derives from the breast TNM classification which defines tumor size >5 cm as T3, being the largest diameter of interest [64] .
Thus, it appears that some factors consistently predict the poor outcome in PB-DLBCL including: Ann-Arbor stage >I E , poor performance status, elevated serum LDH (all included in the aaIPI) and possibly tumor size >4-5 cm. We suggest that these features be used to define higher risk PBL patients.
Careful analysis of published data on the outcome of PB-DLBCL (Table 1) , and indirect comparison with nodal DLBCL, has led us to the conclusion that both categories have a similar prognosis, provided all patients were treated primarily with anthracycline containing regimens followed by radiotherapy (a detailed discussion of the topic is available as a supplementary data, available at Annals of Oncology online).
treatment
Due to the rarity of PB-DLBCL, these patients are often included in localized DLBCL clinical trials, both nodal and extranodal. Therefore, reliable data regarding appropriate treatment of this specific entity are lacking. We performed a comprehensive literature search on therapy for PBL and collected 30 reports detailing treatment modality that were published after the year 2000 [1-5, 7, 10, 13-18, 24, 26, 28, 45-50, 53, 54, 56, 65-69] . The most important and detailed of these are summarized in Tables 1 and 2 .
We posed the following major questions: which single or combined modality of therapy (chemotherapy, radiotherapy and surgery) should be used as primary therapy? Does addition of rituximab to chemotherapy impact PBL outcome? Should central nervous system (CNS) prophylaxis be given routinely?
The following section deals with these key issues. Our major conclusions are highlighted in Table 3 .
choice of systemic therapy
As in nodal forms of DLBCL, an anthracycline-based regimen is the mainstay of treatment, with CHOP being the most frequent regimen used. Most PBL studies report favorably on the administration of systemic chemotherapy even for apparently localized disease. The CISL study concluded that treatment with less than four cycles of chemotherapy had a negative effect on outcome both in terms of 5-year PFS (28% versus 58%; P < 0.001) and OS (19.3% versus 66.2%; P < 0.001) [2] . In the IELSG report, only 70% of patients with PB-DLBCL received an anthracycline and its omission was detrimental in terms of PFS and OS [3] .
A relatively large report from Japan concluded that addition of chemotherapy to surgery improved the 5-year OS in stage I E and II E patients from 40.3% to 57.2% and from 25% to 47%, respectively [13] . Similar analyses from other series support these observations [5, 17, 53, 69] . The only contradictory study was that conducted by the Rare Cancer Network (RCN), which found only a non-significant positive trend for chemotherapy effect on outcome. However, in this study, only 61% of patients with PBL were classified as 'high-grade' lymphoma and not all received anthracyclines, thereby contributing to the borderline results [16] .
The value of rituximab in PB-DLBCL was assessed by only a few studies, including one prospective trial of 32 newly diagnosed patients with PB-DLBCL treated by a dose-dense chemotherapy regimen (R-CEOP-14) and radiotherapy [67] . In this single arm study, the actuarial 3-year event-free survival and OS of 75% and 63%, respectively, were no better than earlier series using less-intensive regimens [66, 70] . No CNS relapses were observed, compared with a rate of 11% in a larger cohort treated without rituximab reported earlier by the same authors [66] . These differences may have been due to the dosedense regimen used in this trial; however, some recent data suggest that rituximab may decrease the rate of CNS relapse in DLBCL, particularly in patients with early-stage disease and low IPI (as most PB-DLBCL patients are) [71] [72] [73] [74] . A comparison of these two prospective trials led the author to conclude that rituximab had no influence on disease-free survival and OS in PB-DLBCL [25] . Similarly, The CISL study failed to record a significant effect of rituximab on OS or PFS, but here the antibody was used preferentially in high-risk patients, which may have masked its overall beneficial effect [2] . A very recent report also found no effect to the addition of rituximab regarding time to progression (TTP) or OS in a study on 75 PB-DLBCL patients, but the authors drew no definitive conclusion from the data due to the small number of patients included [57] . The only report thus far on a possible beneficial effect of rituximab in PBL comes from a retrospective comparison of 20 patients treated with CHOP with or without rituximab. The 5-year survival rate was significantly better for the R-CHOP group, yet once again the small cohort size requires caution in interpreting the results [45] . Disappointingly, the three largest retrospective reports on PB-DLBCL do not refer to the role of rituximab, probably because most of their data were based on older therapeutic regimens [3, 13, 15] .
In conclusion, collected data are clearly in favor of treating with at least four cycles of an anthracycline-based chemotherapy regimen even for stage I E disease. Although not supported by robust data on improved efficacy in PBL, we still favor adding rituximab to chemotherapy, in view of the better overall chance of lymphoma eradication, as well as a possible decrease in the rate of CNS relapse.
the role of radiotherapy and combined modality treatment
The issue of radiotherapy in limited stage DLBCL has been extensively studied, but is still debated. A thorough discussion on advantages and shortcomings of this modality is beyond the scope of our review, but its long-term benefits seem equivocal, Table 3 . Treatment recommendations for PBL 1. Surgery should be minimally invasive and for diagnostic purpose only: core needle or excisional biopsy 2. Further staging should comply with standard staging guidelines for NHL, incorporating the Wiseman-Liao criteria for definition 3. After diagnosis and staging, use systemic therapy with an anthracyclinebased regimen and rituximab 4. Radiotherapy has an important role as adjuvant consolidation therapy, particularly in node-negative (stage I E ) patients 5. Optimal combined modality primary treatment in addition to selection of high-risk patients may obviate the need for routine CNS prophylaxis in all cases. High-risk patients (poor performance status, elevated LDH) may benefit from the addition of CNS prophylaxis Table S1 , available at Annals of Oncology online. Most have given a dose of 30 to 45 Gy, usually to the affected breast with or without regional lymph nodes (i.e. axillary and supraclavicular nodes); however, these variables were never correlated with outcome. The section below will only relate to radiotherapy in general without discussing field or dosage.
Analyzing 465 patients, Jennings et al. showed that the addition of radiotherapy resulted in a trend toward improved OS (47.9% versus 37.1%; P = 0.07), especially in patients without involvement of axillary nodes. The death hazard in stage I E patients was 2.42 times higher (P = 0.002) when radiotherapy was not used; however, this study analyzed a variety of different lymphoma subtypes and did not relate to PB-DLBCL alone [15] . Zhao et al. [45] reported similar results in 31 cases of PBL (90% DLBCL), recording the hazard ratio of 2.32 for death (P = 0.02) in patients whose axillary nodes were not involved and who did not receive radiotherapy.
In the homogenous cohort described in the IELSG report, 130 of 204 patients (64%) received radiotherapy to the involved breast with or without axillary nodes. In multivariate analysis, radiotherapy was found to be associated with a better OS (HR = 0.5; 95% CI: 0.3-1.0; P = 0.03) but not a better PFS (HR = 0.7; 95% CI: 0.4-1.1; P = 0.12) [3] . These unusual results may be related to the fact that 71% of the patients in this study were 'node negative', and OS benefit may have been mostly due to the treatment effect on this large subgroup, as shown in other earlier studies [15, 45] . In the remaining 29% of patients who had involved lymph nodes, radiotherapy did not prevent relapse explaining why PFS was not affected.
The multicenter RCN study reported that radiotherapy improved the local control of PBL but not OS or PFS. The 51 patients who received radiotherapy had a 5-year OS of 58% compared with 46% in 33 non-irradiated patients (P = not significant); however, the 5-year local control rate was 95% versus 76%, respectively (P = 0.005). Similarly, Salzberg et al. [57] found that radiotherapy improved TTP but not OS, possibly due to effective salvage regimen. In contrast, other small series' reports found no positive effects of irradiation, although this may have been due to the small sample size [2, 14, 17] .
The only randomized trial using radiotherapy conducted in PB-DLBCL was published by Aviles et al. in 2005 [66] . Patients were randomized to three arms: radiotherapy only (45 Gy to breast and its lymphatic drainage), chemotherapy only (six cycles of CHOP every 21 days) and combined modality (CMT) (six cycles of CHOP and radiotherapy of 30Gy). The study was planned for 189 patients but was stopped early because interim analysis on 96 patients revealed a higher CR and OS and a lower relapse rate in the CMT arm. CR rates were 66%, 59% and 88% (P = 0.01); 5-year EFS 50%, 57% and 83% (P < 0.01) and 5-year OS were 50%, 50% and 83%, respectively (P < 0.01). These clearly superior results of CMT are in agreement with the observations reported by the IELSG which demonstrated superior outcomes for the subgroup of patients with anthracycline-based regimens and consolidative radiotherapy [3] . Several other studies have also noted the beneficial effect of combined treatment on outcome, supporting this treatment strategy [16, 53, 55, 69] . In contrast, a large analysis of 92 reports published from 1972 to 2005 did not reveal a statistically significant impact of CMT. Although radiotherapy was used in 47% of patients and chemotherapy in almost 70%, their combined use was lower than expected which probably reflects the degree of clinicians' bias against using both modalities at that time [15] . In summary, radiotherapy appears to have a positive impact on the outcome of PB-DLBCL, especially in patients without axillary node involvement (stage I E ). The data on the role of irradiation for DLBCL in the rituximab era are still immature, but in light of results of the clinical trials and observations on PBL mentioned above, we feel it should still be recommended as an adjuvant to systemic (immuno)chemotherapy for localized disease. We are unable to recommend the optimal dose or fields of irradiation for PBL with currently available data.
role of surgery PBL usually presents as a breast mass and lacks specific clinical and radiological diagnostic features [10, 30, 48, 57, 82, 83] . Many patients are initially treated as breast cancer patients, and indeed, of 29 publications reviewed, 24 described surgery as the primary (and sometimes only) treatment modality used. As shown in Table 1 , nearly 30% of PB-DLBCL patients underwent surgical procedures ranging from lumpectomy with axillary dissection to either simple, modified/radical or radical mastectomy. Jennings et al. [15] described that mastectomy was carried out in 156 of the 465 (33.5%) patients reported in the literature and that the procedure was associated with a trend toward worse OS (P = 0.055). Furthermore, the IELSG data showed that radical mastectomy was associated with an increased risk of death, with HR = 2.4 (95% CI: 1.2-4.8; P = 0.03) on multivariate analysis [3] . A comprehensive report from Japan revealed that surgery was carried out in 333 of 380 cases (87.6%), and it was evident that axillary node dissection did not improve outcome [13] . In 2008, Avenia et al. reported better outcomes of quadrantectomy compared with mastectomy in a cohort of 23 patients with PBL. However, it should be noted that these small patient groups were not compared directly, consisted of various lymphoma subtypes, and were not equally balanced. As a result, no conclusions can be drawn on the efficacy of surgery for DLBCL in this particular cohort [7] .
In conclusion, surgery should only be used for diagnosis and must be minimally invasive as extensive surgery carries a high morbidity rate, without any proven advantage over lumpectomy alone. Axillary dissection has no role in the treatment of PB-DLBCL. Surgery should not be regarded as a therapeutic modality, and if it has been performed due to the misdiagnosis of breast carcinoma, subsequent systemic therapy should always be given.
the role of CNS prophylaxis
The role and details of CNS prophylaxis in DLBCL has been extensively covered in many recent comprehensive reviews [84] [85] [86] [87] [88] . Here, we address the question of whether CNS relapse rates are indeed higher in PB-DLBCL, warranting upfront CNS prophylaxis, as many clinicians advocate [14, 67, [86] [87] [88] [89] [90] . Tomita et al. [90] recently described a hazard ratio of 10.5 for CNS relapse in patients with lymphomatous breast involvement. Two of the important trials in PB-DLBCL have reported a rate of 11.5%-13.3% of CNS relapse [57, 66] . In contrast, in some of the largest series of patients with PB-DLBCL, the incidence of was only 4%-5%, similar to that of nodal DLBCL [3, 71, 91] . Others have claimed that in their experience CNS prophylaxis is not justified [26, 47] and there is currently no consensus on this topic.
We identified 24 reports dealing with CNS relapse in PB-DLBCL presented in Table 4 [1-5, 14, 16-18, 24, 26, 28, 41, 46-49, 53, 56, 57, 66, 67, 69, 92, 93] . Overall, it was observed in 82 of the 930 patients reported, accounting for 8.8% of cases. These figures should be interpreted cautiously due to the retrospective nature of most reports, but it seems that CNS relapse occurs in about 5%-10% of patients with PB-DLBCL. Considering a 'background' rate of 3%-5% in DLBCL [71, 91, 94] , we can indeed doubt whether this higher relapse rate justifies the addition of prophylaxis in all cases of PB-DLBCL. Because of the dismal prognosis of CNS relapse [42, 94] , it seems that prevention is the preferred strategy. However, it could be argued that even if the true rate is 10%, still 90% of patients would be overtreated. The doubts worsen with the growing number of reports showing that prophylaxis is probably ineffective [1, 53, 57, 87] along with emerging data, suggesting that the addition of rituximab to chemotherapy may decrease the rate of CNS relapse [42, 67, 71, 72, 74] .
It is of interest to note that a survey among 158 physicians treating lymphoma in the UK revealed that only 7% gave routine CNS prophylaxis when DLBCL involved the breast . These are extremely low figures compared with the rate of prophylaxis given when other extranodal sites like paranasal sinuses (88%), testis (85%), orbital cavity (78%) or bone marrow (65%) were involved [95] .
In summary, although no definite policy has been widely accepted, it appears that in the absence of other risk factors such as high IPI score, elevated LDH or poor performance status, patients with stage I E and II E PBL need not routinely receive CNS prophylaxis and we support this approach.
general conclusions
This review summarized the data on primary breast DLBCL, emphasizing on the more recent reports. Although this lymphoma subtype has some special characteristics, it cannot be regarded as a different entity. With more collaborative studies providing additional data, it may well be recognized as such in the future.
It appears that the prognosis of PB-DLBCL is generally comparable with that of nodal DLBCL and that standard treatment should consist of immunochemotherapy with an anthracycline-based regimen and include consolidation with radiotherapy especially in stage I E patients.
In patients with established CNS relapse risk factors we still favor the use of CNS prophylaxis, yet it seems that past routine prophylaxis recommendations need to be re-assessed. A suggested algorithm on work-up, stratification and treatment of newly diagnosed PB-DLBCL is provided (Figure 1 ), based on insights gained from this extensive literature review. The data could provide a useful guide for clinicians treating this rare disease.
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